Vertex goes back to drawing board after axing another phase II drug June 11, 2021 By Richard Staines It’s back to the drawing broad for Vertex Pharmaceuticals Inc. and its efforts to develop treatments for the rare disease alpha-1-antritrypsin deficiency (AATD), after its VX-864 produced disappointing results in a phase II trial.Read More
